Evidence map›Paper›PMID 37737059›Full record

ArticleCancer medicine2023

Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.

Nina Grundmann, Sven Voigtländer, Amir Hakimhashemi, Ulrich-Frank Pape, Martin Meyer, Jacqueline Müller-Nordhorn

Abstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nina GrundmannBavarian Cancer Registry, Bavarian Health and Food Safety Authority, Nuremberg, Germany.ORCID 0000-0002-5715-2406
Sven VoigtländerBavarian Cancer Registry, Bavarian Health and Food Safety Authority, Nuremberg, Germany.ORCID 0000-0003-3808-9605
Amir HakimhashemiBavarian Cancer Registry, Bavarian Health and Food Safety Authority, Nuremberg, Germany.
Ulrich-Frank PapeDepartment of Internal Medicine and Gastroenterology, Asklepios Tumour Centre Hamburg and Asklepios Hospital St. Georg, Hamburg, Germany.
Martin MeyerBavarian Cancer Registry, Bavarian Health and Food Safety Authority, Nuremberg, Germany.
Jacqueline Müller-NordhornBavarian Cancer Registry, Bavarian Health and Food Safety Authority, Nuremberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeuroendocrine neoplasms (NEN) are rare and heterogeneous epithelial tumors, occurring throughout the body. For gastroenteropancreatic (GEP)-NEN, rising incidence rates were reported for the last decades, with underlying causes remaining largely unexplained. We evaluated NEN trends stratifying by their histologic subtypes.

methodsIncident cases of GEP-NEN diagnosed between 2005 and 2019 were retrieved from the prospective, population-based Bavarian Cancer Registry. GEP-NEN were divided in their histologic subtypes, that is, neuroendocrine tumors (NET) G1, NET G2/G3, other NET versus small-cell neuroendocrine carcinoma (NEC), large-cell NEC, and other NEC. We calculated annual age-standardized incidence rates (ASIRs) per 100,000 persons for the total of GEP-NEN, NEN histologic subtypes, and tumor sites. We used an annual percentage change (APC) approach including a joinpoint analysis to investigate NEN incidence trends.

resultsASIR of GEP-NEN rose from 2.2 in 2005 to 4.8 in 2019, characterized by a significant increase until 2012 (APC 2005-2012: 10.1%), followed by modest rise (APC 2012-2019: 1.5%). In the last decade, this increase was mainly driven by the rise of NET G1 and G2/G3, while incidence for NEC declined. Over the study period, ASIR increased significantly for all GEP-sites except the colon. APCs were largest for the stomach, the appendix, the pancreas, and the rectum.

conclusionsThis study found a significant increase in the incidence of GEP-NET. Though this development may partially be attributable to the increased use of advanced detection techniques and changes in NEN classification, further research should also focus on the identification of NEN risk factors.

Indexed as

Carcinoma, NeuroendocrineIntestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsHumansProspective Studiesgastroenteropancreatic neuroendocrine tumorgastrointestinal neoplasmsincidenceneuroendocrine carcinomaneuroendocrine tumors

Identifiers

PMID37737059
PMCPMC10587981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.